Lubiprostone - Mallinckrodt
Alternative Names: Amitiza; LUBOWEL; RU-0211; SPI-0211; SPIRU-211Latest Information Update: 05 Nov 2023
At a glance
- Originator Sucampo Pharmaceuticals
- Developer Mallinckrodt plc; Sucampo Pharmaceuticals; Takeda
- Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Monounsaturated fatty acids; Prostaglandins; Small molecules
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Constipation; Irritable bowel syndrome
- Discontinued Postoperative ileus